SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending following reports of a major initiative aimed at boosting the mortgage bond market and lowering interest rates to stimulate housing demand. This has ignited significant excitement among the community, which is actively discussing a potential short squeeze and a robust rebound for the real estate sector.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending following an FDA notification about deficiencies precluding labeling discussions for its Anaphylm drug, just weeks before its PDUFA date. While this news caused a significant stock drop, many in the community view it as an overreaction to minor "labeling semantics," asserting that the FDA would not engage in such detailed discussions if approval wasn't likely. The immediate focus is on how quickly these issues can be resolved for the potentially transformative needle-free epinephrine film, with the FDA confirming the review remains ongoing.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending after announcing a significant agreement with Meta to develop a 1.2-gigawatt power campus for AI data centers, driving conversation around the future of nuclear energy. This deal has ignited strong community debate over Oklo's speculative valuation, given its pre-revenue status, versus its long-term potential to address the escalating energy demands of the AI sector with advanced nuclear technology.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending amid extreme volatility and a significant price decline, with many in the community citing aggressive market 'manipulation' or 'fkkery'. Despite some expectations for a 'polar payday' driven by potential colder weather, the leveraged ETF faces relentless selling pressure, prompting discussions of capitulation, impending reverse splits, and its inherent decay as it tracks natural gas futures.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending due to a significant institutional investment, including a $1 billion stock and warrant sale priced above market, and its subsidiary Airobotics securing a prime contract for Israel's border security "Drone Hives" program. This has ignited strong community conviction, with many interpreting the premium paid and high warrant strike price as signals for substantial future appreciation in the autonomous defense sector, despite some discussions around short-term dilution.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending as the market increasingly recognizes small modular reactors (SMRs) as a vital solution for the escalating energy demands of AI data centers. Community discussions highlight NuScale's unique position as the sole NRC-approved SMR technology, with recent positive developments like a Virginia energy award for a NuScale simulator and broader U.S.-Japan nuclear investment commitments fueling both investor interest and debates over long-term valuation and potential dilution.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is buzzing following significant new agreements to secure vast amounts of long-term nuclear energy, a critical move to power its rapidly expanding data centers and burgeoning AI infrastructure. This strategic embrace of clean, reliable power is driving community conversation, highlighting the increasing energy demands of hyperscalers and sparking diverse opinions on its financial implications and impact on the broader nuclear sector.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Aptevo Therapeutics Inc

Aptevo Therapeutics (APVO) is trending following news of securing a $60 million equity line of credit, which some view as a critical funding boost for its pipeline while others fear it signals further dilution. The company's extremely low share float after a recent reverse split has ignited significant community discussion around a potential short squeeze, despite ongoing concerns about historical shareholder value and the nature of the new financing.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited ($ANPA) is trending due to explosive price action, reminiscent of previous low-float Hong Kong IPOs. The community is actively debating whether this is a parabolic squeeze driven by a tightly held float or a classic pump and dump, with many comparing its extreme volatility to other recent "China plays." Despite discussions of a potential rug pull, investors are closely watching its unusual market behavior, fueling intense conversation around its rapid movements.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending after securing all regulatory approvals for its Renergen acquisition, which expands its portfolio into helium and LNG alongside its core isotope business. The community is actively discussing this, alongside a recent "Overweight" rating from Cantor Fitzgerald, as ASPI aims to be a critical supplier of HALEU and specialized isotopes for the growing nuclear and tech sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies

GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.

Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by Zacks Research

Zacks Research lowered Keros Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday...

Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.3% - Time to Sell?

Keros Therapeutics (NASDAQ:KROS) Trading Down 3.3% - What's Next...

Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics

AES and four peers screen as low price-to-book buys, highlighting undervalued stocks with solid growth profiles as 2025 draws to a close.

Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Drops By 16.6%

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) saw a large drop in short interest in December. As of December 15th, there was short interest totaling 2,692,419 shares, a drop of 16.6% from...

5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close

AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.

KROS or ARGX: Which Is the Better Value Stock Right Now?

KROS vs. ARGX: Which Stock Is the Better Value Option?

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports...

Assenagon Asset Management S.A. Has $4.07 Million Holdings in Keros Therapeutics, Inc. $KROS

Assenagon Asset Management S.A. increased its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 154.2% during the 3rd quarter, according to the company in its most recent disclosure...

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why

Keros Therapeutics (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Keros Therapeutics Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$18.58
Prev Close	$18.56
Open	$18.53
Dividend Yield	0.00%
50-Day Moving Average	$18.48
Beta	0.88
Avg. Volume	721,573.45
PE Ratio	12.04

52-Week High	$22.55
52-Week Low	$9.12
Market Capitalization	$566.06M
EPS (Annual)	-$5.00
Price to Book	1.07
Revenue Per Employee	$21,005.92
Enterprise Value/EBITDA	N/A

KROS
Keros Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KROS News

KROSKeros Therapeutics Inc